CG Oncology

CG Oncology formerly known as Cold Genesys is a privately held, clinical-stage biopharmaceutical company that focuses on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies.

CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already been completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.

CG Oncology headquartered in United States, North America, operates in the Biotechnology, Health Care, Health Diagnostics, Oncology sector. The company focuses on Biotechnology and has secured $35.6B in funding across 112 round(s). With a team of 51-100 employees, CG Oncology is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - CG Oncology, raised $13.6M. Discover more about their projects, partnerships, and impact on our platform.